METASTATIC SOLID TUMOR

This study is testing whether a combination of two drugs, tucatinib and T-DM1, can help control solid tumors that have spread to the brain. It is for up to 30 adults with HER2-positive metastatic cancer who have brain metastases that do not require immediate surgery or radiation.…

This is the first study in people for a new drug called KK2269. It aims to find a safe dose and see how well the body tolerates it. The study will test KK2269 alone in people with various advanced solid tumors, and also test it combined with a standard chemotherapy drug (docetaxe…

This is an early-stage study to test a new drug called BGB-B455 in people with advanced solid tumors that have a specific protein called CLDN6. The main goals are to find a safe and effective dose and to understand what side effects participants experience. The drug is designed t…

This is the first human study of a new experimental drug called XB628, designed to help the immune system fight cancer. The trial will test different doses of the drug in 75 people with advanced solid tumors that have returned or spread after previous treatments. The main goals a…

This early-stage trial is testing a new oral medication called MOMA-313, given alone or with an existing cancer drug (olaparib), in people with advanced solid tumors that have stopped responding to other treatments. The main goal is to find safe dose levels and see how the body p…

This is the first study in people testing a new oral drug called NVL-330 for advanced lung cancer that has a specific genetic change called HER2. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the dr…

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This is the first study in people to test a new oral medication called CID-078 for advanced solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. The study will enroll adults with cancers like triple-negative breast cancer, small cell lu…

This early-stage study is testing the safety and initial effects of a new drug called SYN818 when given with an existing cancer drug, olaparib. It is for adults with advanced or metastatic solid tumors (like ovarian or breast cancer) that have specific genetic changes (BRCA mutat…

This early-stage study is testing the safety and early effectiveness of an experimental drug called IL12-L19L19 in people with advanced solid tumors that have spread. The trial is for patients whose cancer has continued to grow despite receiving standard immunotherapy. Researcher…

This is the first human study testing a new cancer drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial will enroll 540 participants to determine safe dosage levels and see if the drug helps control cancer growth. R…

This is the first study in people testing a new cancer drug called AGX101. It aims to find a safe and effective dose for patients with advanced solid tumors that have spread or cannot be removed by surgery, and who have no other standard treatment options left. The drug is given …

This is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see …

This is a first-in-human study testing a new drug called CLSP-1025 for adults with advanced solid tumors that have a specific genetic change called the p53 R175H mutation. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug works by en…

This study is testing a new oral medication called NVL-655 for people with advanced cancers that have a specific genetic change called ALK. The trial aims to find the safest and most effective dose and see how well the drug shrinks tumors. It's for adults with advanced lung cance…

This study is testing a new, experimental drug called GI-101 in people with advanced cancers that have spread. The main goals are to find a safe dose and see if the drug, given alone or with other approved cancer medicines, can help shrink tumors. The trial will enroll about 317 …

This early-stage trial is testing a new immune therapy drug called ADU-1805, both alone and combined with an existing cancer drug (pembrolizumab). It aims to find safe doses and see if the treatment helps control advanced solid tumors that haven't responded to standard treatments…

This study is testing a new type of radiation therapy called lattice radiation (LRT) for people with large cancer tumors that have spread to soft tissues. It compares LRT to standard radiation to see which is better at shrinking tumors and attracting immune cells to fight the can…

This is an early-stage safety study for a new drug called ANK-101, which is injected directly into tumors. It aims to find a safe dose for people with advanced solid cancers that have stopped responding to standard treatments. The study will test the drug alone in different types…

This early-stage study is testing a new drug called GI-108 in people with advanced or spreading solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The main goals are to find a safe dose and see if the drug shows any signs of helping to shrink tumors. The…

This study is testing a new cancer drug called IPN01203 in adults with advanced solid tumors that have spread and stopped responding to standard immunotherapies. Researchers will first find the safest and most effective dose, then test how well the drug controls tumor growth. The…

This study is testing a new drug called LY4050784 for people with advanced solid tumors that have a specific genetic change called a SMARCA4/BRG1 alteration. The main goals are to find a safe dose of the drug, given alone or with other cancer treatments, and to see if it helps sh…

This early-stage study is testing a new drug called IPN60300 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. All participants will receive the dru…

This is a first-in-human study to test the safety and find the right dose of a new investigational drug called LY4052031 for people with advanced or metastatic solid tumors. The drug is designed to target a specific protein found on many cancer cells, delivering its medicine dire…

This is a first-in-human study to test the safety and initial effectiveness of a new drug called BGB-B2033. It will be given alone or in combination with other cancer drugs to people with specific advanced or metastatic solid tumors, including certain liver, lung, stomach, and ge…

This is the first study in people to test a new drug called JZP898. Researchers want to see if it is safe and tolerable when given alone and when combined with an existing immunotherapy drug (pembrolizumab) for adults with advanced or metastatic solid tumors. The main goals are t…

This early-stage study aims to find a safe and effective dose for combining two cancer drugs, niraparib and irinotecan. It is for adults with advanced solid tumors (like certain breast, ovarian, or pancreatic cancers) that have spread and have specific mutations in genes like BRC…

This is an early-stage study testing the safety and initial effectiveness of a new drug called CHS-114 when combined with an existing immunotherapy (toripalimab) and possibly other standard treatments. It is for adults with advanced or metastatic solid tumors, including specific …

This clinical trial is testing an experimental drug called zidesamtinib for people with advanced cancers that have a specific genetic change called ROS1. The study aims to find the safest and most effective dose, and then see how well the drug shrinks tumors in patients with ROS1…

This early-stage study is testing the safety and initial effectiveness of combining two targeted cancer drugs, pemigatinib and afatinib, in people with advanced solid tumors that have specific genetic changes and have stopped responding to standard treatments. The main goals are …

This is the first study in humans to test a new drug called ASD141 for people with advanced solid tumors that have spread and no longer respond to available treatments. The main goal is to find a safe dose and see how the body processes the drug. Researchers will also look for ea…

This is the first human study of an experimental cancer drug called LY4101174. Researchers want to find a safe dose and see if it can help control advanced cancers that have spread or returned after other treatments. The study will enroll about 490 people with various solid tumor…

This is the first human study testing a new oral drug called MOMA-341 for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The main goal is to find safe doses and see how the body handles the drug when taken alone or combined with other cance…

This study is testing a new drug called FMC-376 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe and effective dose and to see if the drug can shrink or control tumors. It is for patients whose cancer ha…

This study is testing whether a new drug called repotrectinib, when given with standard chemotherapy, is safe and effective for children and young adults (up to age 30) whose solid tumors have come back or stopped responding to other treatments. Researchers will first find the sa…

This study is testing if a common acne cream (tretinoin) can prevent or reduce a severe, acne-like rash that is a common and painful side effect of certain cancer drugs. In a unique 'split-face' design, 25 adults with advanced solid tumors will apply the test cream to one side of…

This early-stage study is testing a new imaging agent, 89Zr-DFO-REGN5054, in patients with advanced solid tumors who are receiving the immunotherapy drug cemiplimab. The main goal is to see if the imaging agent is safe and to understand how it moves through the body. Researchers …